Galmed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:GLMD) $0.36 -0.01 (-1.37%) (As of 01:16 PM ET) Add Compare Share Share Today's Range$0.34▼$0.3850-Day Range$0.29▼$0.6652-Week Range$0.26▼$14.18Volume163,309 shsAverage Volume133,266 shsMarket Capitalization$604,800.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Read More GLMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLMD Stock News HeadlinesNovember 24, 2023 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.comNovember 20, 2023 | finance.yahoo.comGalmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 4, 2023 | morningstar.comGalmed Pharmaceuticals Ltd GLMDSeptember 26, 2023 | finance.yahoo.comGalmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisAugust 3, 2023 | nasdaq.comGalmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08July 14, 2023 | marketwatch.comGalmed Pharma Shares Drop 30% After Public Offering PricesJuly 14, 2023 | seekingalpha.comGalmed shares slump on pricing discounted stock and warrants offeringNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comJuly 14, 2023 | finance.yahoo.comGalmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingJuly 13, 2023 | investorplace.comWhy Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?July 10, 2023 | finance.yahoo.comGalmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCJuly 3, 2023 | bizjournals.comMadrigal begins process seeking OK for multibillion-dollar — yet elusive — NASH drugJune 3, 2023 | benzinga.comGalmed Pharmaceuticals Stock (NASDAQ:GLMD), Insider Trading ActivityJune 1, 2023 | finanznachrichten.deGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsJune 1, 2023 | msn.comRecap: Galmed Pharmaceuticals Q1 EarningsJune 1, 2023 | finance.yahoo.comGalmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsMay 17, 2023 | thestreet.comWhy Galmed Pharmaceuticals (GLMD) Stock Is Surging TodayMay 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and Haemonetics (HAE)May 9, 2023 | finance.yahoo.comGalmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)May 5, 2023 | msn.comWhy Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?May 4, 2023 | finance.yahoo.comGalmed Pharmaceuticals forms a Strategic Partnership with OnKaiMarch 29, 2023 | finance.yahoo.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022February 17, 2023 | seekingalpha.comGLMD Galmed Pharmaceuticals Ltd.February 8, 2023 | finance.yahoo.comGalmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine SaltJanuary 6, 2023 | finance.yahoo.comCan Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?January 4, 2023 | marketwatch.comGalmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol StudySee More Headlines Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/01/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLMD CUSIPN/A CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.7793) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.61% Return on Assets-48.40% Debt Debt-to-Equity RatioN/A Current Ratio6.79 Quick Ratio3.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.20 per share Price / Book0.04Miscellaneous Outstanding Shares1,680,000Free Float1,347,000Market Cap$609,840.00 OptionableNot Optionable Beta0.95 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Allen Baharaff (Age 58)Co-Founder, President, CEO & Chairman Comp: $803.5kMr. Doron Cohen (Age 56)Chief Financial Officer Comp: $175.33kMr. Guy Nehemya (Age 38)COO & Data Protection Officer Comp: $235.56kMr. Yohai Stenzler CPA (Age 40)Chief Accounting Officer Comp: $239.48kDr. Liat Hayardeny (Age 56)Chief Scientific Officer Comp: $125.24kMs. Yael Hollander (Age 40)Vice President of Legal Affairs & Strategy Comp: $134.21kMs. Shani GanonHuman Resources ManagerDr. Tali Gorfine (Age 53)Medical Consultant Comp: $202.76kMore ExecutivesKey CompetitorsContraFectNASDAQ:CFRXOncorusNASDAQ:ONCRTharimmuneNASDAQ:THARBaudax BioNASDAQ:BXRXBellerophon TherapeuticsNASDAQ:BLPHView All CompetitorsInstitutional OwnershipWalleye Capital LLCBought 249,763 shares on 11/21/2023Ownership: 14.867%View All Institutional Transactions GLMD Stock Analysis - Frequently Asked Questions Should I buy or sell Galmed Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GLMD shares. View GLMD analyst ratings or view top-rated stocks. How have GLMD shares performed in 2023? Galmed Pharmaceuticals' stock was trading at $7.50 at the beginning of the year. Since then, GLMD shares have decreased by 95.2% and is now trading at $0.3630. View the best growth stocks for 2023 here. Are investors shorting Galmed Pharmaceuticals? Galmed Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 12,900 shares, an increase of 17.3% from the October 31st total of 11,000 shares. Based on an average trading volume of 165,600 shares, the short-interest ratio is currently 0.1 days. Approximately 0.4% of the shares of the stock are sold short. View Galmed Pharmaceuticals' Short Interest. When is Galmed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our GLMD earnings forecast. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) posted its earnings results on Thursday, June, 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.41. When did Galmed Pharmaceuticals' stock split? Galmed Pharmaceuticals's stock reverse split before market open on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP). Who are Galmed Pharmaceuticals' major shareholders? Galmed Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Capital LLC (14.87%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GLMD) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.